BOSTON--(BUSINESS WIRE)--Solu Therapeutics, a precision-medicine company developing therapeutics to eliminate disease-driving cells, founded by Longwood Fund, today announced the closing of an ...

Six years ago, Brandon Turunen, PhD, answered a call from his employer, GSK, for proposals to develop new medicines. “They would oftentimes do calls for new ideas amongst the company to look for new ...

Solu Therapeutics has debuted with $31 million in seed financing to develop a small-molecule drug technology licensed from GSK. Called Cytotoxicity Targeting Chimera, or CyTaC, the technology results ...

OFFICER Media Group's mission is to provide the most valuable and reliable information available for law enforcement news, training, operations and innovations. Through our website, electronic ...